Explore timely topics in liver disease in a lively debate format as hepatology trainees and practicing hepatologists tackle important, often controversial issues. Debaters will gain skills in critical thinking, balanced argumentation and factual examination of each issues' pros and cons. Debaters, judges and audience members will grapple with opposing scientific, societal, individual and financial viewpoints on current clinical concerns.
Sarah S. Jackson, Ruth M. Pfeiffer, Chiara Gabbi, Lesley Anderson, Shahinaz M. Gadalla, Jill Koshiol – 10 November 2021
Sarah S. Jackson, Ruth M. Pfeiffer, Chiara Gabbi, Lesley Anderson, Shahinaz M. Gadalla, Jill Koshiol – 10 November 2021
Robert S. Brown – 10 November 2021
10 November 2021
Sarah Bernards, Ryutaro Hirose, Francis Y. Yao, Chengshi Jin, Jennifer L. Dodge, Chiung‐Yu Huang, Neil Mehta – 10 November 2021 – As a result of ongoing regional disparities, the United Network for Organ Sharing (UNOS) implemented policy in May 2019 limiting exception points for waitlisted patients with hepatocellular carcinoma (HCC) to median Model for End‐Stage Liver Disease at transplant in the area surrounding a transplant center minus 3 points (MMAT‐3). The impact of this policy change remains unknown.
Hui Li, Tian Lan, Hailing Liu, Chang Liu, Junlong Dai, Lin Xu, Yunshi Cai, Guimin Hou, Kunlin Xie, Mingheng Liao, Jiaxin Li, Jiwei Huang, Kefei Yuan, Genshu Wang, Yong Zeng, Hong Wu – 9 November 2021
David Tabernero, Maria Francesca Cortese, Ariadna Rando‐Segura, Maria Buti, Francisco Rodríguez‐Frías – 9 November 2021
Nilay Danis, Sharon R. Weeks, Ahyoung Kim, Azarakhsh Baghdadi, Maryam Ghadimi, Ihab R. Kamel, Behnam Saberi, Tinsay Woreta, Jacqueline Garonzik‐Wang, Benjamin Philosophe, Ahmet Gurakar, Rohit Loomba – 8 November 2021 – To reduce waitlist mortality, living donor liver transplantation (LDLT) has increased over the past decade in the United States, but not at a rate sufficient to completely mitigate organ shortage. As a result, there are ongoing efforts to expand the living liver donor pool.
Coskun Ozer Demirtas, Gabrielle Ricco, Osman Cavit Ozdogan, Feyyaz Baltacioglu, Tunc Ones, Perran Fulden Yumuk, Ender Dulundu, Sinan Uzun, Pierro Colombatto, Filippo Oliveri, Maurizia Rosanna Brunetto, Feyza Gunduz – 8 November 2021 – Optimal scoring system for clinical prognostic factors in patients with unresectable hepatocellular carcinoma (HCC) is currently uncertain. We aimed to develop and externally validate an easy to use tool, particularly for this population, and named it the “unresectable hepatocellular carcinoma prognostic index” (UHPI).